Published in AIDS on January 28, 2012
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med (2013) 2.60
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14
Canadian consensus statement on HIV and its transmission in the context of criminal law. Can J Infect Dis Med Microbiol (2014) 1.68
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention. PLoS Med (2015) 1.50
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection. Milbank Q (2013) 1.33
HIV infection and older Americans: the public health perspective. Am J Public Health (2012) 1.31
When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med (2013) 1.30
Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis (2014) 1.25
Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS One (2015) 1.24
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ (2012) 1.23
Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011. BMC Public Health (2013) 1.23
Early identification of HIV: empirical support for jail-based screening. PLoS One (2012) 1.15
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res (2012) 1.09
Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev (2013) 1.08
HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05
Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med (2013) 1.05
Management of nontuberculous mycobacterial infection in the elderly. Eur J Intern Med (2014) 1.04
Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study. Lancet Glob Health (2014) 1.01
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet (2013) 0.97
Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. AIDS Res Hum Retroviruses (2013) 0.96
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One (2013) 0.96
Linkage to care following a home-based HIV counselling and testing intervention in rural South Africa. J Int AIDS Soc (2015) 0.93
Identification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of U.S.-based studies, 1996-2011. AIDS Behav (2014) 0.93
Towards Multidisciplinary HIV-Cure Research: Integrating Social Science with Biomedical Research. Trends Microbiol (2015) 0.91
Improvements in depression and changes in quality of life among HIV-infected adults. AIDS Care (2014) 0.88
Processes and outcomes of developing a continuity of care document for use as a personal health record by people living with HIV/AIDS in New York City. Int J Med Inform (2012) 0.87
Low levels of HIV test coverage in clinical settings in the U.K.: a systematic review of adherence to 2008 guidelines. Sex Transm Infect (2014) 0.87
Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis (2014) 0.86
Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis (2015) 0.86
Health outcomes for HIV-infected persons released from the New York City jail system with a transitional care-coordination plan. Am J Public Health (2015) 0.85
Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A Randomized Controlled Trial. J Acquir Immune Defic Syndr (2016) 0.84
Gender difference in advanced HIV disease and late presentation according to European consensus definitions. Sci Rep (2015) 0.84
Feasibility and success of HIV point-of-care testing in an emergency department in an urban Canadian setting. Can J Infect Dis Med Microbiol (2013) 0.84
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS (2013) 0.84
Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One (2012) 0.83
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. AIDS Res Hum Retroviruses (2012) 0.82
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. PLoS One (2015) 0.82
High Concordance between Self-Reported Adherence, Treatment Outcome and Satisfaction with Care Using a Nine-Item Health Questionnaire in InfCareHIV. PLoS One (2016) 0.81
Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy. Cell Biosci (2012) 0.81
Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol (2015) 0.81
Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications. Front Immunol (2013) 0.81
Adult male circumcision in Nyanza, Kenya at scale: the cost and efficiency of alternative service delivery modes. BMC Health Serv Res (2014) 0.79
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. AIDS Res Ther (2015) 0.79
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis (2016) 0.78
Treatment as prevention--where next? Curr HIV/AIDS Rep (2014) 0.78
Exposing the gaps in awareness, knowledge and estimation of risk for anal cancer in men who have sex with men living with HIV: a cross-sectional survey in Australia. J Int AIDS Soc (2015) 0.78
Population-Based Estimates of Life Expectancy After HIV Diagnosis: United States 2008-2011. J Acquir Immune Defic Syndr (2016) 0.77
Risk factors for "late-to-test" HIV diagnosis in Riverside County, California. Medicine (Baltimore) (2016) 0.77
Evaluating the utility of provider-recorded clinical status in the medical records of HIV-positive adults in a limited-resource setting. Int J STD AIDS (2016) 0.76
Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa. PLoS One (2016) 0.76
Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study. BMJ Open (2013) 0.76
Lifetime HIV antiretroviral therapy adherence intervention: timing is everything: comment on "Managed problem solving for antiretroviral therapy adherence". JAMA Intern Med (2013) 0.76
The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS. Viral Immunol (2014) 0.76
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol (2016) 0.75
AIDS and HIV Infection after Thirty Years. AIDS Res Treat (2013) 0.75
Recent Tobacco Smoking is Associated with Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York. AIDS Behav (2016) 0.75
Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland - Data from Test and Keep in Care (TAK) Project. PLoS One (2016) 0.75
Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect Dis (2016) 0.75
Resource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: a micro-costing study. BMC Health Serv Res (2015) 0.75
Sexual behaviour of people living with HIV attending a tertiary care government hospital in Kathmandu, Nepal: a cross sectional study. BMC Res Notes (2015) 0.75
Determinants of antiretroviral therapy coverage in Sub-Saharan Africa. PeerJ (2015) 0.75
A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model. Epidemiology (2016) 0.75
A discrete choice experiment to assess people living with HIV's (PLWHIV's) preferences for GP or HIV clinic appointments. Sex Transm Infect (2016) 0.75
Are HIV-infected men vulnerable to prostate cancer treatment disparities? Cancer Epidemiol Biomarkers Prev (2014) 0.75
Five-year risk of HIV diagnosis subsequent to 147 hospital-based indicator diseases: a Danish nationwide population-based cohort study. Clin Epidemiol (2016) 0.75
Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010. BMJ Open Diabetes Res Care (2017) 0.75
The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study. BMC Infect Dis (2014) 0.75
Smoking: A Major Roadblock in the Fight Against AIDS. Nicotine Tob Res (2016) 0.75
Antiretroviral therapy: Shifting sands. Med J Armed Forces India (2016) 0.75
Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. PLoS One (2015) 0.75
Chronic Binge Alcohol-Induced Dysregulation of Mitochondrial-Related Genes in Skeletal Muscle of Simian Immunodeficiency Virus-Infected Rhesus Macaques at End-Stage Disease. Alcohol Alcohol (2017) 0.75
Efficacy of a Social Self-Value Empowerment Intervention to Improve Quality of Life of HIV Infected People Receiving Antiretroviral Treatment in Nepal: A Randomized Controlled Trial. AIDS Behav (2017) 0.75
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. J Int AIDS Soc (2016) 0.75
Women, Aging, and HIV: Clinical Issues and Management Strategies. J Nurse Pract (2014) 0.75
Economic and health implications from earlier detection of HIV infection in the United Kingdom. HIV AIDS (Auckl) (2016) 0.75
HIV Testing and awareness of HIV status among people who inject drugs in greater Kuala Lumpur, Malaysia. AIDS Care (2017) 0.75
Validation of Retention in HIV Care Status Using the New York City HIV Surveillance Registry and Clinical Care Data From a Large HIV Care Center. J Public Health Manag Pract (2017) 0.75
[HIV testing of the general population: international recommendations and actual risks for HIV infections in health occupations]. Wien Med Wochenschr (2013) 0.75
Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study. J Int AIDS Soc (2017) 0.75
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res (2017) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med (2011) 5.28
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS (2005) 2.96
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 2.76
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 2.70
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med (2015) 2.62
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
Chronic renal failure among HIV-1-infected patients. AIDS (2007) 2.07
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol (2005) 2.02
When should antiretroviral therapy for HIV be started? BMJ (2007) 1.95
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS (2009) 1.81
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS (2011) 1.68
Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J (2011) 1.64
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer (2010) 1.53
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52